Tevogen Bio Holdings Inc. (TVGN)

NASDAQ: TVGN · Real-Time Price · USD
1.340
+0.030 (2.29%)
At close: May 29, 2025, 4:00 PM
1.330
-0.010 (-0.75%)
After-hours: May 29, 2025, 6:56 PM EDT
2.29%
Market Cap 246.42M
Revenue (ttm) n/a
Net Income (ttm) -31.28M
Shares Out 183.89M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 416,658
Open 1.290
Previous Close 1.310
Day's Range 1.290 - 1.350
52-Week Range 0.256 - 3.090
Beta -0.80
Analysts Strong Buy
Price Target 10.00 (+646.27%)
Earnings Date Jun 10, 2025

About TVGN

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. The company was founded in ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 18
Stock Exchange NASDAQ
Ticker Symbol TVGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for TVGN stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target
$10.0
(646.27% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a planned expansion of TVGN 489's target population to include patient...

6 days ago - GlobeNewsWire

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of the...

7 days ago - GlobeNewsWire

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets and ...

17 days ago - GlobeNewsWire

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that, following the Company's recent press release highlighting the Dir...

27 days ago - GlobeNewsWire

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of inten...

4 weeks ago - GlobeNewsWire

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today informed shareholders about several differences between holding shares in Dire...

4 weeks ago - GlobeNewsWire

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth ...

4 weeks ago - GlobeNewsWire

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 bil...

4 weeks ago - GlobeNewsWire

Tevogen Bio Announces 2025 Annual Meeting

WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced that the Company will hold its 2025 annual meeting of stockholder...

4 weeks ago - GlobeNewsWire

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced it has entered into an agreement with CD 8 Technology Services L...

6 weeks ago - GlobeNewsWire

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics and ...

6 weeks ago - GlobeNewsWire

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States

WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announces its newest effort: Tevogen Generics. This effort is in response to t...

7 weeks ago - GlobeNewsWire

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

WARREN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and artificial intellig...

7 weeks ago - GlobeNewsWire

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission

WARREN, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and artificial intellig...

7 weeks ago - GlobeNewsWire

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven im...

2 months ago - GlobeNewsWire

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven im...

2 months ago - GlobeNewsWire

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

WARREN, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today announced the fi...

2 months ago - GlobeNewsWire

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage...

2 months ago - GlobeNewsWire

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. TVGN, a clinical-stage immunotherapy company.

3 months ago - Benzinga

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

WARREN, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, announced in January 2025, it ...

3 months ago - GlobeNewsWire

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

WARREN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, announced today that it...

3 months ago - GlobeNewsWire

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

WARREN, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, aims to set new efficie...

3 months ago - GlobeNewsWire

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy ...

3 months ago - GlobeNewsWire

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the...

3 months ago - GlobeNewsWire

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

CEO of Tevogen Bio, Dr. Saadi addresses short selling and its potential impact on the nation's health and prosperity. Reaffirms commitment to shareholders.

3 months ago - GlobeNewsWire